151 related articles for article (PubMed ID: 36321230)
1. Acteoside (Verbascoside): A Prospective Therapeutic Alternative against Hepatocellular Carcinoma by Inhibiting the Expression of AXL, FGFR, BRAF, TIE2 and RAF1 Targets.
Kityania S; Nath R; Nath D; Patra JK; Talukdar AD
Comb Chem High Throughput Screen; 2023; 26(10):1907-1919. PubMed ID: 36321230
[TBL] [Abstract][Full Text] [Related]
2. Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study.
Ma D; Wang J; Liu L; Chen M; Wang Z
BMC Cancer; 2020 Sep; 20(1):936. PubMed ID: 32993568
[TBL] [Abstract][Full Text] [Related]
3. Integrated System Pharmacology Approaches to Elucidate Multi-Target Mechanism of
Khalid HR; Aamir M; Tabassum S; Alghamdi YS; Alzamami A; Ashfaq UA
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234758
[TBL] [Abstract][Full Text] [Related]
4. Prediction of sorafenib treatment-related gene expression for hepatocellular carcinoma: preoperative MRI and histopathological correlation.
Dong Z; Huang K; Liao B; Cai H; Dong Y; Huang M; Zhou X; Jia Y; Xu L; Luo Y; Li ZP; Feng ST
Eur Radiol; 2019 May; 29(5):2272-2282. PubMed ID: 30547202
[TBL] [Abstract][Full Text] [Related]
5. Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies.
Gnoni A; Licchetta A; Memeo R; Argentiero A; Solimando AG; Longo V; Delcuratolo S; Brunetti O
Medicina (Kaunas); 2019 Nov; 55(12):. PubMed ID: 31766556
[TBL] [Abstract][Full Text] [Related]
6. miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation.
Ghousein A; Mosca N; Cartier F; Charpentier J; Dupuy JW; Raymond AA; Bioulac-Sage P; Grosset CF
Liver Int; 2020 Jan; 40(1):240-251. PubMed ID: 31612616
[TBL] [Abstract][Full Text] [Related]
7. Molecular docking and dynamic simulations of
Sangeetha R; Arockia Jeya Yasmi Prabha E; Lakshmi A; Sangavi P; Langeswaran K
J Biomol Struct Dyn; 2022; 40(24):13997-14012. PubMed ID: 34738880
[TBL] [Abstract][Full Text] [Related]
8. Bioinformatic and experimental data decipher the pharmacological targets and mechanisms of plumbagin against hepatocellular carcinoma.
Zhou R; Wu K; Su M; Li R
Environ Toxicol Pharmacol; 2019 Aug; 70():103200. PubMed ID: 31158732
[TBL] [Abstract][Full Text] [Related]
9. Overexpressed or hyperactivated Rac1 as a target to treat hepatocellular carcinoma.
Sauzeau V; Beignet J; Vergoten G; Bailly C
Pharmacol Res; 2022 May; 179():106220. PubMed ID: 35405309
[TBL] [Abstract][Full Text] [Related]
10. Network pharmacological evaluation of strigolactones efficacy as potential inhibitors against therapeutic targets of hepatocellular carcinoma.
Amod A; Pahal S; Choudhary P; Gupta A; Singh S
Biotechnol Lett; 2022 Jul; 44(7):879-900. PubMed ID: 35672528
[TBL] [Abstract][Full Text] [Related]
11. Molecular Docking and Dynamics Simulation Analysis of Thymoquinone and Thymol Compounds from Nigella sativa L. that Inhibits P38 Protein: Probable Remedies for Hepatocellular Carcinoma.
Tabassum H; Ahmad IZ
Med Chem; 2020; 16(3):350-357. PubMed ID: 31038073
[TBL] [Abstract][Full Text] [Related]
12. Multilevel data integration and molecular docking approach to systematically elucidate the underlying pharmacological mechanisms of Er-Zhi-Wan against hepatocellular carcinoma.
Zheng S; Pan B
Aging (Albany NY); 2022 Nov; 14(21):8783-8804. PubMed ID: 36347033
[TBL] [Abstract][Full Text] [Related]
13. [Study on molecular mechanism of Solanum nigrum in treatment of hepatocarcinoma based on network pharmacology and molecular docking].
Liu JH; Lyu DY; Zhou HM; Kuang WH; Chen ZX; Zhang SJ
Zhongguo Zhong Yao Za Zhi; 2020 Jan; 45(1):163-168. PubMed ID: 32237426
[TBL] [Abstract][Full Text] [Related]
14. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target.
Xue ST; Li K; Gao Y; Zhao LY; Gao Y; Yi H; Jiang JD; Li ZR
Autophagy; 2020 Oct; 16(10):1823-1837. PubMed ID: 31986961
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.
Casadei Gardini A; Chiadini E; Faloppi L; Marisi G; Delmonte A; Scartozzi M; Loretelli C; Lucchesi A; Oboldi D; Dubini A; Frassineti GL; Ulivi P
BMC Cancer; 2016 Jul; 16():429. PubMed ID: 27388325
[TBL] [Abstract][Full Text] [Related]
16. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
17. An advanced network pharmacology study to explore the novel molecular mechanism of Compound Kushen Injection for treating hepatocellular carcinoma by bioinformatics and experimental verification.
Lu S; Meng Z; Tan Y; Wu C; Huang Z; Huang J; Fu C; Stalin A; Guo S; Liu X; You L; Li X; Zhang J; Zhou W; Zhang X; Wang M; Wu J
BMC Complement Med Ther; 2022 Mar; 22(1):54. PubMed ID: 35236335
[TBL] [Abstract][Full Text] [Related]
18. Yupingfeng San exhibits anticancer effect in hepatocellular carcinoma cells via the MAPK pathway revealed by HTS
Pei T; Dai Y; Tan X; Geng A; Li S; Gui Y; Hu C; An J; Yu X; Bao X; Wang D
J Ethnopharmacol; 2023 Apr; 306():116134. PubMed ID: 36627003
[TBL] [Abstract][Full Text] [Related]
19. Computational assessment of chemicals from
Ugwah-Oguejiofor CJ; Chukwuka EP; Onifade OF; Agu ST; Adegboyega AE; Johnson GI; Ogunsuyi OI; Johnson TO
J Biomol Struct Dyn; 2023; 41(22):13271-13286. PubMed ID: 36709454
[TBL] [Abstract][Full Text] [Related]
20. Exploring the mechanisms underlying the therapeutic effect of the
Qing L; Pan B; He Y; Liu Y; Zhao M; Niu B; Gao X
Aging (Albany NY); 2022 Nov; 14(22):9103-9127. PubMed ID: 36403263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
